This patent describes compositions derived from the submucosa of various mammals that possess growth factors useful for the expansion of stem cells.
This patent teaches that submucosa matrix proteins are useful for expanding islet cells in vitro. This technology may allow the use of pancreatic stem cells to generate large amounts of islets for treatment of patients with Type 1 diabetes.
This patent teaches that by crosslinking various portions of MHC II on differentiated cells, the cells will dedifferentiate and increase the number of CD34 stem cells. This patent, if the data is reproducible, could revolutionize stem cell therapy. The company currently developing this patent is called TriStem.
Alpha-fetoprotein (AFP) is a 65-kDa oncofetal glycoprotein found in fetal and maternal fluids during pregnancy and is produced by various types of cancers. This patent is useful for parties seeking methods of inducing proliferation of bone marrow cells. Particularly, AFP may be used to stimulate hematopoiesis in patients, as well as potentially for regenerative...
This patent covers the use of HGF for stimulation of hematopoietic stem cell proliferation, as well as differentiation along the erythroid lineage. This patent may be useful for the treatment of anemia, as well as post hematopoietic stem cell ablation patients.
This patent teaches the use of HOX11 cell populations for identifying genes that control stem cell proliferation and differentiation.
This patent covers ways of culturing an embryoid body that is derived from embryonic stem cells, in order to generate a type of cell that gives rise to hematopoietic lineage stem cells and differentiated cells.
This patent covers the use of the c-kit ligand together with stimulators of gp130 for the in vitro and ex vivo expansion of hematopoietic stem cells. Since the c-kit ligand is important for other types of stem cells, it will be interesting to see if this patent can be used for expansion of, say for example, cardiac stem cells.
This patent is directed towards the culture of avian embryonic stem cells. The patent has two independent claims. The first is a culture medium for avian embryonic stem cells comprising of FGF-2, IGF-1; at least one cytokine selected from LIF, IL-11, IL-6, CNTF, and oncostatin M (OSM)) and...
This patent covers ways of identifying expression of the gene patched inside cells. This is important since various stem cells, embryonic tissues, and cancer cells express this gene in its wildtype or mutated form. The manipulation of the patched pathway can be used for stem cell differentiation and/or expansion.